

June 20, 2019

To: Office of the Vermont Attorney General
AGO.highcostprescriptiondrugs@vermont.gov

From: Sage Therapeutics, Inc.
Jeffrey Burt (Jeffrey.Burt@sagerx.com)
Senior Director, Pricing & Contracting
215 First St.
Cambridge, MA 02142

Re: Notice of a New Prescription Drug Pursuant to 18 V.S.A. § 4637(b)

Sage Therapeutics, Inc. ("Sage Therapeutics") submits this notice pursuant to 18 V.S.A. § 4637(b), which requires prescription drug manufacturers to provide the Office of the Vermont Attorney General written notice within three calendar days of releasing a drug in the commercial market whose Wholesale Acquisition Cost ("WAC") exceeds the threshold set for a specialty drug under the Medicare Part D Program.

Sage Therapeutics released ZULRESSO™ (brexanolone) injection CIV 20 mg/mL into the commercial market on June 20, 2019. The WAC per vial for ZULRESSO exceeds the threshold set for a specialty drug under the Medicare Part D Program.